Biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Friday that its drug Tezspire (tezepelumab), developed in partnership with Amgen, met both co-primary endpoints in the Phase III WAYPOINT trial for chronic rhinosinusitis with nasal polyps (CRSwNP). The trial showed that Tezspire delivered a statistically significant and clinically meaningful reduction in nasal polyp size and nasal congestion compared to placebo.

The WAYPOINT trial, a randomised, double-blind, placebo-controlled study, evaluated the efficacy and safety of Tezspire in adults with severe CRSwNP who were symptomatic despite standard treatments. Tezspire was administered via subcutaneous injection, and the safety profile observed was consistent with previous studies.

Full results will be shared with regulatory authorities and the scientific community at an upcoming medical conference. Tezspire, currently approved for severe asthma in multiple regions, including the US, EU and Japan, is also under development for other indications, such as chronic obstructive pulmonary disease (COPD) and eosinophilic esophagitis.

Tezspire works by targeting thymic stromal lymphopoietin (TSLP), a cytokine implicated in the inflammation of diseases like asthma and CRSwNP. The results from the WAYPOINT trial further support its potential as a treatment for a range of immune-mediated conditions.

AstraZeneca and Amgen continue to share costs and profits equally for Tezspire under their collaboration agreement, with AstraZeneca leading its development.